Trial Profile
A Pan Asian Trial Comparing Efficacy and Safety of Insulin NN1250 and Insulin Glargine as Add on to OAD(s) in Subjects With Type 2 Diabetes (BEGIN: ONCE ASIA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-ONCE-ASIA
- Sponsors Novo Nordisk
- 12 Jun 2012 The non-inferiority of insulin degludec and insulin glargine in the primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 22 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.